Scientific Hypothesis for Treatment of COVID‐19′s Lung Lesions by Adjusting ACE/ACE2 Imbalance
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Scientific Hypothesis for Treatment of COVID‐19′s Lung Lesions by Adjusting ACE/ACE2 Imbalance
Authors
Keywords
-
Journal
Cardiovascular Toxicology
Volume 21, Issue 6, Pages 498-503
Publisher
Springer Science and Business Media LLC
Online
2021-04-09
DOI
10.1007/s12012-021-09649-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Drugs acting on the renin–angiotensin system and SARS-CoV-2
- (2021) A. Vitiello et al. DRUG DISCOVERY TODAY
- Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade
- (2021) A. Vitiello et al. HUMAN IMMUNOLOGY
- Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?
- (2021) Antonio Vitiello et al. IRISH JOURNAL OF MEDICAL SCIENCE
- Efficacy of synthetic glucocorticoids in COVID-19 endothelites
- (2021) Francesco Ferrara et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19
- (2021) Antonio Vitiello et al. MEDICAL HYPOTHESES
- Colchicine and SARS-CoV-2: Management of the hyperinflammatory state
- (2021) Antonio Vitiello et al. RESPIRATORY MEDICINE
- Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target
- (2020) Haibo Zhang et al. INTENSIVE CARE MEDICINE
- Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
- (2020) Qiurong Ruan et al. INTENSIVE CARE MEDICINE
- Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury
- (2020) Yingxia Liu et al. Science China-Life Sciences
- B38-CAP is a bacteria-derived ACE2-like enzyme that suppresses hypertension and cardiac dysfunction
- (2020) Takafumi Minato et al. Nature Communications
- Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2
- (2020) Vanessa Monteil et al. CELL
- Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
- (2020) Alexandra C. Walls et al. CELL
- SARS ‐CoV‐2 receptor ACE 2 and TMPRSS 2 are primarily expressed in bronchial transient secretory cells
- (2020) Soeren Lukassen et al. EMBO JOURNAL
- Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis
- (2020) Xiu-wu Pan et al. INTENSIVE CARE MEDICINE
- Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis
- (2020) Jing Yang et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China
- (2020) Hua Su et al. KIDNEY INTERNATIONAL
- Multiorgan and Renal Tropism of SARS-CoV-2
- (2020) Victor G. Puelles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased ACE2 Expression in the Bronchial Epithelium of COPD Patients who are Overweight
- (2020) Andrew Higham et al. Obesity
- Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection
- (2020) Xin Zou et al. Frontiers of Medicine
- Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)
- (2020) Tao Guo et al. JAMA Cardiology
- Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China
- (2020) Shaobo Shi et al. JAMA Cardiology
- The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2
- (2020) Francesco Ferrara et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Systematic profiling of ACE2 expression in diverse physiological and pathological conditions for COVID‐19/SARS‐CoV‐2
- (2020) Yunjin Li et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- ACE2 Expression Is Increased in the Lungs of Patients With Comorbidities Associated With Severe COVID-19
- (2020) Bruna G G Pinto et al. JOURNAL OF INFECTIOUS DISEASES
- Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis
- (2020) Jiuyang Xu et al. Frontiers of Medicine
- Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?
- (2020) Antonio Vitiello et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Remdesivir and COVID-19
- (2020) Francesco Ferrara et al. IRISH JOURNAL OF MEDICAL SCIENCE
- Therapeutic Strategies for SARS-CoV-2 acting on ACE-2
- (2020) A. Vitiello et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Remdesivir versus ritonavir/lopinavir in COVID-19 patients
- (2020) Antonio Vitiello et al. IRISH JOURNAL OF MEDICAL SCIENCE
- Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19
- (2020) A. Vitiello et al. LIFE SCIENCES
- Angiotensin-(1-7) Inhibits Thrombin-Induced Endothelial Phenotypic Changes and Reactive Oxygen Species Production via NADPH Oxidase 5 Downregulation
- (2017) Wan-Yu Pai et al. Frontiers in Physiology
- The Effect of Endogenous Angiotensin II on Alveolar Fluid Clearance in Rats with Acute Lung Injury
- (2016) Jia Deng et al. Canadian Respiratory Journal
- Angiotensin-(1-7) attenuates airway remodelling and hyperresponsiveness in a model of chronic allergic lung inflammation
- (2015) G S Magalhães et al. BRITISH JOURNAL OF PHARMACOLOGY
- Angiotensin-Converting Enzyme 2 Attenuates Bleomycin-Induced Lung Fibrosis in Mice
- (2015) Lifang Wang et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Angiotensin-Converting Enzyme 2/Angiotensin-(1-7)/Mas Axis Protects against Lung Fibrosis by Inhibiting the MAPK/NF-κB Pathway
- (2013) Ying Meng et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human Subjects
- (2013) Manuel Haschke et al. CLINICAL PHARMACOKINETICS
- Renin–angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease
- (2012) Dinesh Shrikrishna et al. CLINICAL SCIENCE
- Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis
- (2012) D. Caldeira et al. BMJ-British Medical Journal
- Macrophage Polarization by Angiotensin II-Type 1 Receptor Aggravates Renal Injury-Acceleration of Atherosclerosis
- (2011) Suguru Yamamoto et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started